News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RENB $1.34 HOD $1.47 #Nasdaq Market Outlook #Bullish- BUY. The last pattern detected was #bullish with positive implications. The overall evidence is very high that there will be signal for a STRONG BUY soon.
$RENB #informative #newsfeed #scientific #cancer #immunotherapy #studies#Nadaq Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy!
$RENB #Undervalued https://www.tipranks.com/news/the-fly/renovaro-biosciences-amsterdam-umc-cancer-center-announce-intended-partnership
$RENB $1.50 +2.04% Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy #MarketScreener https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Inc-and-Amsterdam-UMC-Cancer-Center-Poised-to-Advance-Cancer-Immunotherapy-46818916/?utm_source=twitter&utm_medium=social&utm_campaign=share #Gedicube #Renovaro
$RENB Advancing Cancer Immunotherapy in Collaboration with Amsterdam UMC Cancer Center; Creating a “NEWCO”: Nasdaq: RENB
$RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics
Renovaro Biosciences Inc (NASDAQ:RENB) with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center and will benefit from the combined resources, expertise, and extensive”— The Hon. Mark Dybul, MD, CEOLOS ANGELES,, CALIFORNIA, UNITED STATES, May 24, 2024 /EINPresswire.com/ -- Advancing Cancer Immunotherapy in Collaboration with Amsterdam UMC Cancer Center; Creating a “NEWCO”: Renovaro, Inc. (Nasdaq: RENB)
$RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics
For more information on this Exciting NASDAQ Company: RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
* Focus on Personalized Medicine for Longevity Powered by Mutually Reinforcing AI and Biotechnology Platforms.
* Plans to Acquire 100% of Cyclomics for Shared Commitment to Advancing State-of-the-Art Technologies in Cancer Diagnostics and Treatment.
* Relationships with Oxford Nanopore & Nvidia position RENB as a Leader in Early Cancer Diagnostics and Monitoring Treatment Efficacy.
* Introduced Flamingo, a Potentially Groundbreaking Multi-Cancer Detection Model to Transform Early Cancer Diagnostics.
Breaking News:
RENB and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation, any final contractual commitments are subject to approval from both executive boards.
This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, toward innovative advancements in cancer treatment.
The proposed “Newco” will be headquartered in Amsterdam, The Netherlands. By merging Renovaro's cutting-edge vaccine technology with the Cancer Center's expertise, the aim is to develop personalized cancer immunotherapy solutions tailored to individual patients, overcoming immunotherapy resistance.
This new venture will operate independently, with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center, and will benefit from the combined resources, expertise, and extensive networks of its parent organizations, ensuring a strong foundation for success.
Both Renovaro and the Amsterdam UMC Cancer Center believe that the commitment to driving innovation in more non-invasive cancer therapies will enable significant strides in the fight against cancer, offering hope to patients worldwide.
Renovaro, Inc (Nasdaq: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. RENB brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
RENB has announced a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RENB RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital supercomputing power and front-edge software solutions such as Parabricks, BioNeMo, Monai, and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, RENB believes the acquisition of Cyclomics into the Renovaro family will further strengthen its ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a Novel AI Model Based on Fragmentomics
On April 30th RENB unveiled its Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, the RENB Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo underscores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
RENB believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The RENB Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
The RENB Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, and sequence motifs, and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The RENB Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
RENB RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers, and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
RENB Combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
$RENB News: Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation any final contractual commitments are subject to approval from both executive boards.
This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.
The proposed “Newco” will be headquartered in Amsterdam, The Netherlands. By merging Renovaro's cutting-edge vaccine technology with the Cancer Center's expertise, the aim is to develop personalized cancer immunotherapy solutions tailored to individual patients, overcoming immunotherapy resistance.
"We believe that by combining our expertise in cancer research and therapy with Renovaro's innovative allogenic dendritic vaccine technology, we can accelerate the development of personalized cancer treatments," said Prof. Geert Kazemier, Director of the Amsterdam UMC Cancer Center. "This once again represents our commitment to advancing cancer immunotherapy and improving patient outcomes."
"We are thrilled to partner with the Amsterdam UMC Cancer Center to drive innovation in cancer immunotherapy," said Coenraad K. van Kalken MD PhD, Director of RenovaroCube. "This collaboration represents a recognition of our potentially transformative technologies and a strategic alignment of our shared vision to change cancer treatment through personalized medicine. Also, as part of the MoU certain clinical activities would be moved to Amsterdam."
This new venture will operate independently, with a dedicated team of researchers collaborating closely with experts from both RenovaroBio and the Amsterdam UMC Cancer Center and will benefit from the combined resources, expertise, and extensive networks of its parent organizations, ensuring a strong foundation for success.
Both Renovaro and the Amsterdam UMC Cancer Center believe that the commitment to driving innovation in more non-invasive cancer therapies will enable significant strides in the fight against cancer, offering hope to patients worldwide.
About Renovaro Group:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. We believe this will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Amsterdam UMC/ CCA
With over 16,000 employees and 1,400 beds, Amsterdam UMC is one of the largest University Hospitals in the Benelux. The two locations of Amsterdam UMC, merged in 2020, work together to provide good and accessible care for millions of people. Amsterdam UMC focuses on a future where diseases can be prevented and where patients receive the best treatments. Amsterdam UMC has eight research institutes, the largest being the Cancer Center. The VUmc location (former Free University Hospital) emphasizes cancer and neurodegenerative disease research. The researchers affiliated are internationally recognized among the top in medical scientific research.
The Cancer Center Amsterdam was founded as a research institute over 25 years ago by Prof. Bob Pinedo and his colleagues to pursue innovative cancer research. Today, Cancer Center Amsterdam has become much more than an academic oncology center, encompassing all cancer care, research, and education at Amsterdam UMC. It is also aligned with the Cancer Center Amsterdam Foundation, which raises funds to empower promising developments in oncology research and patient care at Amsterdam UMC, and with Amsterdam UMC Holding, the corporate entity set up to actively bring highly promising medical innovation to the market.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEyMzQ1MyM2MjY4MjU3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/NmVlM2U4YTItMmZkMi00OGY5LTkzNzAtODVkZjA3Y2Y0YjE5LTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB 1.44 +53.19% Finally seeing that bullish move on so much great news and promise by the company. SO many reasons to have RENB on radar, Thank you!
$RENB Discover more with @renovaro @Nasdaq https://t.co/hugpNhp4V9 Top Ten Reasons to Have $RENB on your radar! pic.twitter.com/mznQvlGeqv
— CrusaderX (@CrusaderStocks) April 8, 2024
$RENB - Renovaro Inc. (NASDAQ: RENB) Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- Benzinga #Healthcare #Biopharma #AI #Computing #Power
$RENB -Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- #Benzinga #Healthcare #Biopharma #Cancersucks $NVDA #AI #Computing #Power
$RENB Buy Opinion. Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection #Bullish https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer-
$RENB Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html
It's been an interesting month - Renovaro has focused on completing the Cyclomics deal. The deal has been altered from LOI of 75% to ownership of 100%, and so far so good.
The market has been focused on Russell2000, and whether or not Renovaro made the threshold. Marketcap cut-off was around 140 mio USD, so it looks as if RENOVARO passed the exam easy-peasy. I must admit that as a shareholder it didn't quite feel that way - when the stock traded at 1.30 I was worried sick .
But the Ranking day is one thing - reconstitution end of June is another.
So right now the company MUST be focused on funding, and in the meantime, short-sellers are doing their best to make that a nightmare for existing shareholders. I hope that whoever ends up buying in to Renoovaro pays more than the present "hammered" price - but time will tell
$RENB $1.525 HOD $1.58 RENOVARO IS TRANSFORMING CANCER DETECTION: RENOVAROCUBE INTRODUCES FLAMINGO, A NOVEL #AI MODEL BASED ON FRAGMENTOMICS https://renovarobio.com/news/transforming-cancer-detection-renovarocube-introduces-flamingo-a-novel-ai-model-based-on-fragmentomics/
$RENB Great Volume early! Headed for another huge day.
$RENB Closed Higher on NEWS! Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel #AI model based on Fragmentomics https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
@YahooFinance
#RenovaroInc
@Nasdaq
#AI #News #Healthcare #CancerDetection #Cancer #FDA
$RENB 1.695 +8.65% on NEWS - RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics ; Transforming Cancer Detection https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
https://www.globenewswire.com/newsroom/ti?nf=OTEwODQ5OCM2MjI2Njk4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OThkZGJkYzMtMDEzYi00YTcxLThhZWEtZDdmMDQ2ZDA4NzdlLTExMzIyNTA=/tiny/Renovaro-Inc.png
Source: Renovaro Inc
$RENB Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI - https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai/ Renovaro (Nasdaq: RENB) is a trailblazer in AI-driven early cancer diagnostics and therapeutics #cancer #FDA
@nasdaq
$RENB NEWS: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership https://finance.yahoo.com/news/renovarocube-acquire-100-ownership-cyclomics-130000419.html
Good morning $RENB.
$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
Renovaro Biosciences Inc.
Thu, April 18, 2024 at 8:45 AM EDT
In this article: RENB
+5.41%
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$RENB stock market is rallying $2.90 +5.07% HOD $2.93
$RENB $2.94 +5.38% Continuing bullish momentum this week.
$RENB $2.84 +2.53% Renovaro’s mission is to aim to develop definitive, long-term remission therapies for cancers and infectious diseases. https://renovarobio.com/
$RENB $2.82 GEDiCube’s award winning #AI is developing high-performance biomarker panels for 13 different cancers. GEDi Cube Intl Ltd. a London & Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB) https://axecapitalusa.com/renb/ $GDHG $NRXP $DIS
$RENB resilient @ $2.69 0.04 (1.51%) HOD $2.72 #shortsqueeze
$RENB GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb
$RENB #AI Pioneer GEDiCube/ RenovaroCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine https://renovarobio.com/news/ai-pioneer-gedicube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelerate-personalized-medicine/
$RENB $3.19 +8.50% closing the week bullish! #shortsqueeze
$RENB $3.17 open. GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb @ein_news
$GRTX $JANX $ZVSA $ADN $IFBD $PUBM $SRFM $TMDX $HOLO $AKLI $BSGM
$RENB New HOD $3.05 +1.67% $RENB Great article out summarizing Renovaro Biosciences - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
https://ir.renovarogroup.com/news/news-details/2024/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace/default.aspx
$RENB $3.04 HOD $3.13 Renovaro Inc. (NASDAQ:RENB) shares shot up 4% during trading. The company traded as high as $3.13 and last traded at $3.04.
$RENB opens higher $2.58 +11.69% #bullish
$RENB $2.50 +.29 +13.12% Weekly Chart is Bullish.
$RENB heading for $3.00's soon!
$RENB $2.38 +8.18% In early trading #TuesdayVibes
$RENB green in power hour!
$RENB $2.19 +6.07% GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
Cyclomics has developed a groundbreaking diagnostic method for monitoring early cancer recurrence named “CyclomicsSeq”- a novel ctDNA (circulating tumor DNA is tumor-derived fragmented DNA in the bloodstream that is not associated with cells) detection assay based on Oxford Nanopore sequencing which delivers fast, low-cost, and point-of-care sequencing. In contrast to available ctDNA-based methods, “CyclomicsSeq” ensures that even a single ctDNA molecule in the blood can be detected at very high accuracy. This solution consists of a new diagnostic kit (CyclomicsSeq), which has been licensed to Oxford Nanopore (LON: ONT), an RNA/DNA next-generation sequencing platform company.
$RENB
$RENB Great volume and price action this week!
$RENB 2.15 ready to go!
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
$RENB
$RENB Breakthrough Testing with Nvidia AI Chips, Cyclomics and GEDICube; Early Cancer Detection: Renovaro: NASDAQ: RENB
https://www.einpresswire.com/article/690522470/breakthrough-testing-with-nvidia-ai-chips-cyclomics-and-gedicube-early-cancer-detection-renovaro-nasdaq-renb via @ein_news
$RENB 2.17 ready to fall!
$RENB - Renovaro Biosciences Collaborates with NVIDIA Partner GEDiCUBE for Advanced Cancer Diagnosis: (Nasdaq: RENB) https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb via @ein_news $NVDA
|
Followers
|
5
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
196
|
|
Created
|
12/02/17
|
Type
|
Free
|
| Moderators Trooperstocks | |||
Renovaro Inc.
Renovaro is driven by an unwavering commitment to revolutionize healthcare. Our primary objectives encompass pioneering advancements in AI, diagnostics and therapies for patients with cancer.
RenovaroCube
Renovaro Cube is commited to use liquid biopsies for the full patient journey.
RenovaroBio
RenovaroBio has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
From Strength to Strength
Both RenovaroCube and RenovaroBio are at the forefront of oncology innovations, revolutionizing the field of cancer treatment. RenovaroBio is committed to a future where survival is increased the toxic effects of chemotherapy are eliminated. They are focused on developing next-generation diagnostics and immunotherapy, specifically dendritic cell-based therapy, as an alternative to chemotherapy.
RenovaroCube is dedicated to develop the next generation of diagnostics for early detection of the disease, treatment selection, response prediction and follow-up of disease spanning the full patient journey using only one simple vial of blood (liquid biopsies). Collectively we offer a holistic approach to cancer treatment, benefiting not only patients but also clinicians and healthcare providers by employing a vertically integrated approach.
Our mission
Integrating the power of AI from diagnosis through treatment and recovery
Our Goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
To impact patients from diagnostics through theraputic intervention
A future free from toxic Chemotherapy
Detection of diseases before the appearance of symptoms
Non-invasive liquid biopsy testing
Our Team
COMMITTED TO RADICALLY ACCELERATE PRECISION MEDICINE
Maurice van Tilburg – Glimne
Chairman
David Weinstein
Director & Chief Executive Officer (CEO)
Douglas W. Calder
Director
Mark Collins, Phd
Director
James A. McNulty
Director
Simon Tarsh
Interim Chief Financial Officer (CFO)
Company
GEDiCube and Cyclomics Forge Alliance, Spearheading Global Liquid Biopsy Market
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
“Our Omni-Omic technology was developed to help empower AI platforms and thereby transform non-invasive healthcare solutions to detect cancers and other diseases as early as possible. GEDiCube’s innovative deep learning algorithms have created robust multi-omics panels that perform remarkably well. Together, I believe we will change the field.”
“There is enormous power in applying AI to multiple omics data layers that can be detected from a vial of blood from every patient with cancer. I believe that integrating Cyclomics into GEDiCube will allow us to gain greater accuracy and widespread Omni-omic measurements through next-generation sequencing and enter the cancer monitoring market this year. I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”
By Coenraad van Kalken, MD, PhD, the CEO of GEDiCube
About Cyclomics
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence, thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
About GEDiCube
At GEDiCube, we are committed to the early detection of cancer, to intervene at a stage where treatment can be most effective. We have developed an award-winning AI Technology that significantly accelerates early cancer detection and diagnosis at an early stage and its recurrence via liquid biopsy. Our platform, “ The Cube,” brings together proprietary artificial intelligence (AI/ML) technology and algorithms, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to accelerate precision medicine and enable breakthrough changes in cancer care. As of this morning GEDiCube will operate under its new name, RenovaroCube.
Top Reasons to Have RENB on Your Radar RIGHT NOW
Cutting-Edge Innovation: Renovaro Biosciences is at the forefront of medical innovation, spearheading advanced allogeneic cell and gene therapies for cancer, HIV, and HBV.
Transforming Healthcare: By reshaping immune responses and aiming for a future free from toxic chemotherapy, RENB is driving transformative changes in healthcare, offering hope for millions worldwide.
Market Potential: With a focus on a multi-billion dollar market opportunity, RENB is strategically positioned to capitalize on significant growth prospects in the healthcare sector.
Clinical-Stage Advancements: As a clinical-stage company, RENB has made substantial progress in developing transformative therapies, with several candidates advancing through preclinical and clinical phases.
Cancer Treatment Revolution: RENB's groundbreaking therapies offer hope for patients battling cancer, with promising developments in solid tumor treatments that could revolutionize cancer care.
HIV Breakthroughs: With innovative approaches to gene-modified cell therapies for HIV, RENB is pioneering potential cures and preventive measures, addressing a critical need in global healthcare.
HBV Gene Therapy: RENB's exploration of gene therapy for HBV showcases its commitment to tackling infectious diseases, presenting a promising avenue for combating Hepatitis B virus infections.
Strategic Partnerships: Collaborations with renowned institutions like UCLA and the Fred Hutchinson Cancer Research Center underscore RENB's commitment to leveraging top-tier expertise in advancing its therapies.
Platform Technology: RENB's sophisticated allogeneic cell therapy platforms offer scalable and cost-effective solutions, enhancing accessibility and effectiveness in treating various diseases.
Investor Appeal: With a NASDAQ listing (NASDAQ: RENB), RENB presents an attractive investment opportunity, backed by its innovative pipeline, strategic partnerships, and potential for significant market growth.
The Opportunity…
Renovaro Biosciences Inc (NASDAQ: RENB) presents an unparalleled opportunity in the rapidly evolving landscape of healthcare innovation. With a focus on advanced allogeneic cell and gene therapies, RENB is poised to address critical unmet needs in the treatment and prevention of cancer, HIV, and HBV.
In a market with multi-billion dollar potential, RENB stands out as a pioneering force, leveraging cutting-edge technology to develop transformative therapies. Its clinical-stage advancements demonstrate tangible progress in bringing these therapies to fruition, offering hope for patients worldwide.
One of RENB's most promising areas of focus is its revolutionary approach to cancer treatment. By targeting solid tumors with genetically modified cell therapies, RENB aims to reshape the landscape of cancer care, potentially offering life-changing outcomes for patients. Moreover, its commitment to innovative HIV therapies reflects a dedication to addressing the ongoing challenges of managing this chronic disease, with the ultimate goal of achieving a cure.
The exploration of HBV gene therapy further underscores RENB's commitment to tackling infectious diseases, with the potential to impact millions affected by Hepatitis B virus infections. Through strategic partnerships with leading institutions such as UCLA and the Fred Hutchinson Cancer Research Center, RENB leverages top-tier expertise to drive forward its research and development efforts.
With a NASDAQ listing (NASDAQ: RENB), RENB offers investors a compelling opportunity to participate in the future of healthcare. Its innovative pipeline, strategic collaborations, and potential for significant market growth make RENB an attractive investment proposition. By transforming healthcare and offering hope for a future free from toxic chemotherapy, RENB is poised to make a profound impact on the lives of millions worldwide.
If there is a way to prevent this devastating disease from happening, it could completely change the healthcare landscape going forward. This is where Renovaro Biosciences Inc (NASDAQ: RENB) is leading in innovation.
Company Overview:
Renovaro Biosciences Inc. (NASDAQ: RENB) is a pioneering biotechnology company at the forefront of revolutionizing healthcare. Focused on developing advanced allogenic cell and gene therapies, Renovaro is committed to addressing significant unmet needs in cancer, HIV, and HBV treatment. With a strategic emphasis on innovative technologies and cutting-edge research, the company is reshaping the landscape of modern medicine.
Renovaro's mission is anchored in its dedication to transforming cancer care. By leveraging groundbreaking gene-modified cell therapies, the company aims to offer hope to patients battling solid tumors, a critical area where traditional treatments often fall short. Additionally, Renovaro's pioneering approach to HIV treatment presents a potential breakthrough in combating the virus and improving patient outcomes worldwide.
Committed to advancing healthcare, Renovaro collaborates with renowned institutions such as UCLA and the Fred Hutchinson Cancer Research Center. Through these strategic partnerships, the company accelerates the development of its therapies and maximizes their potential to impact patients' lives positively.
As a NASDAQ-listed company (NASDAQ: RENB), Renovaro offers investors a compelling opportunity to participate in the dynamic field of biotechnology. With a focus on innovation, collaboration, and market growth, Renovaro is poised to lead the way in transforming healthcare and shaping a brighter future for patients worldwide.
ADVANCED ALLOGENEIC CELL THERAPY
The strategic benefit of cell therapy platforms is to potentially allow for manufacture of large, “off-the-shelf” banks of therapeutic cells that could be accessed on demand by health care professionals to potentially decrease the time between diagnosis and treatment.
In addition, because we focus on cells from donors, the strategy could potentially enhance the ability of the therapeutic candidates to induce a more robust response once injected into patients. The human immune system is designed to recognize and distinguish “self” from “non-self” and destroy “otherness” such as bacteria, viruses, and damaged or diseased cells such as cancer cells. Alloreactivity (reacting against another person’s cells) is the most powerful response the immune system generates.
Several of our technologies take advantage of the alloreactivity to hyper stimulate a person’s immune response to better attack a chronic infection (e.g., HIV) or solid tumor. In certain proposed treatments in development (e.g., HIV and cancer), cells taken from healthy donors are sometimes genetically modified to introduce signaling molecules that are designed to enhance the ability of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.
Renovaro believes that the combination of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate therapeutic candidates that have unique attributes that will increase the likelihood of success.
CELL THERAPY ENABLING TECHNOLOGY
In addition to the platform described above, Renovaro has an innovative gene therapy approach to enhance the selection and engraftment (uptake) of cells carrying therapeutic attributes. Enhanced uptake or engraftment could play a critical role in some cases to increase the likelihood of therapeutic benefit. This technology was initially developed for autologous cell therapy from a person living with HIV, and genetically modifying those cells so they cannot be infected with most variants of HIV, plus a gene modification to enhance uptake. We have sublicensed under a profit-sharing agreement our technology to potentially increase engraftment for potential use in CAR-T therapy as a potential cure for HIV.
HBV GENE THERAPY
Renovaro is exploring various approaches for gene therapy design elements to potentially eliminate virus-infected cells with an innovative molecular mechanism that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection and exacerbate disease.
LEVERAGING BANKED (OFF-THE-SHELF) ALLOGENIC CELL THERAPY
Leveraging allogenic cells offers numerous advantages to our development strategy:
Boosting Immunity: Non-self allogenic cells bolster T-Cells, activating immune responses effectively.
Enhanced Safety Potential: Allogenic cells, naturally rejected after stimulating cancer-killing cells, don't permanently reside in the body, possibly improving safety.
Expedited Therapy Access: Cryopreserved dendritic cell banks enable swift therapy post-diagnosis, reducing waiting times. Scalable production from a single donor source ensures cost-effectiveness compared to autologous cell therapy.
Versatile Platform: Our platform, primed to receive any tumor antigen, facilitates rapid development of multiple products for various cancer types
Renovaro BioSciences collaborates with Dr. Anahid Jewett from UCLA to further investigate the efficacy of our approach in pancreatic cancer. Dr. Jewett's innovative mouse model mimics the human immune system, offering invaluable insights for advancing cancer treatment.
Unmatched efficacy for therapeutic vaccines in preclinical models for human solid tumors
RENB-DC11 treated animals compared to controls
Untreated tumor
Tumor treated with untransduced Dendritic Cells (mainstream cancer vaccine approach)
Tumor treated with vector control transduced Dendritic Cells
80-90% decreases pancreas tumor size (weight and volume)
Significant infiltration of tumor sac by effector immune cells
Significant peripheral T and NK Cell immune activation
No metastases
Delayed injection of RENB-DC11 in mice with established luciferase labeled pancreas tumor, stopped progression and showed drastic tumor size regression in 2/3 mice (one mouse had no tumor detection 4wk post dosing), whereas all untreated mice showed massive tumor progression.
Revolutionizing Infectious Disease Treatment: Unveiling Renovaro Biosciences' Groundbreaking Platform for Combatting Viral Threats!
"Despite advances in treatment, HIV remains a global challenge. Antiretroviral therapy has transformed HIV from a death sentence to a manageable condition, yet it comes with challenges such as lifelong therapy, high costs, and risks of side effects. With drug resistance on the rise, there's a critical need for innovative solutions. Stigma and discrimination further complicate the situation.
Over 40% of those needing therapy lack access, and HIV claims over a million lives annually with millions more newly infected. A cure or preventive vaccine holds the promise of transforming countless lives worldwide."
RENB-HV-12: PREVENTIVE AND THERAPEUTIC VACCINES
Allogeneic Cell Therapy Platform
Renovaro BioSciences aims to boost the immune system against HIV through vaccination, offering protection for uninfected individuals and potentially controlling the virus in those already infected. Their innovative approach utilizes immune response induction from donor cells. Promising in vitro results have led to non-human primate studies at the Fred Hutchinson Cancer Research Center, with preliminary findings expected by late 2023. Human studies could follow in late 2024
RENB-HV01: AUTOLOGOUS TRANSPLANT WITH GENETICALLY MODIFIED CELLS
"Renovaro BioSciences presents a groundbreaking solution for HIV treatment by targeting CCR5 expression, crucial for HIV entry into cells. Their ALDH gene modification technology aims to enhance engraftment of gene-modified stem cells without the need for immune system ablation, potentially eliminating the need for Antiretroviral Treatment (ART). While initial studies showed promising results, further development of RENB-HV01 was deemed costly. As a strategic move, Renovaro sub-licensed the ALDH gene modification to Caring Cross, who aims to integrate it into their CAR-T cell therapy for enhanced engraftment."
RENB-HV21: IMMUNOTHERAPY WITH ALLOGENEIC NK/GDT CELLS
Allogeneic Cell Therapy Platform
"Renovaro BioSciences is exploring RENB-HV21, a promising HIV treatment utilizing allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). These cells, believed to play a key role in controlling the virus, offer innovative potential for HIV therapy. Renovaro holds an exclusive license for the underlying patent, with successful pre-IND studies completed. However, due to priority shifts to the Oncology pipeline, immediate clinical trials for RENB-HV21 are not planned."
HBV:
RENB-HB01: HBV Gene Therapy
RENB-HB-01 is currently in the early pre-clinical phase, with ongoing exploration of different gene therapy design approaches. Pending successful results from these explorations, we anticipate initiating the regulatory process by the first half of 2024. However, our primary focus and investment priority lie in advancing the oncology platform, starting with pancreatic cancer research and development.
Renovaro Biosciences Targets Expansive Market Opportunities
Renovaro Biosciences: Pioneering Breakthroughs in Pipeline and Technology Platforms
Our integrated platforms encompass innovative interventions in advanced cell and gene therapies that provide hope for cures and/or life-long remissions for devastating diseases. Because of the relative ease of administration, our potentially ground-breaking interventions could be used throughout the world to transform the lives of millions of people.
Revolutionizing Cancer Treatment: Explore Renovaro Biosciences' Innovative Oncology Platform
GENE MODIFIED CELL THERAPIES FOR CANCER / SOLID TUMORS
Currently into IND-enabling phase with planned IND submission H2 2024
Renovaro Biosciences pioneers cutting-edge cancer therapies targeting immune evasion. Our innovative approach, leveraging genetically engineered dendritic cells, bypasses tumor defenses, and enhances tumor eradication. RENB-DC11, a breakthrough therapy, harnesses genetic modifications to bolster immune signaling, effectively targeting aggressive solid tumors.
“The fusion of AI and biotech opens up new horizons in healthcare. We have been advancing strategic partnerships with leading academic centers and technology companies while working to expand our existing relationship with NVIDIA. We believe our combined capabilities will help to accelerate both the ability to detect and treat cancer and other diseases.”
By Dr. van Kalken added,
In summary…
In the realm of modern medicine, the quest to conquer cancer and infectious diseases stands as one of humanity's greatest challenges. Renovaro Biosciences Inc. (NASDAQ: RENB) emerges as a beacon of hope, dedicated to pioneering advanced allogenic cell and gene therapies to combat these formidable foes.
With a comprehensive pipeline spanning oncology, HIV, and HBV, Renovaro is at the forefront of cutting-edge medical innovation. In the oncology sphere, the company's groundbreaking platform targets solid tumors, leveraging genetically modified dendritic cells to bypass immune evasion and enhance tumor eradication. Promising preclinical results from RENB-DC11 demonstrate its efficacy against aggressive forms of solid tumors.
In the battle against HIV, Renovaro's innovative approach seeks to boost immune responses through preventive and therapeutic vaccines, potentially transforming the lives of millions worldwide. Meanwhile, their exploration of allogenic Natural Killer and Gamma Delta T-Cells presents a novel avenue for HIV treatment.
Additionally, Renovaro's foray into HBV gene therapy signals a promising step towards eradicating virus-infected cells, offering hope for those afflicted by this persistent infection.
With a focus on leveraging banked allogenic cell therapy and strategic collaborations with esteemed institutions like UCLA, Renovaro is poised to revolutionize healthcare delivery. As the company advances its mission to develop definitive cures and therapies, now is the time to keep Renovaro Biosciences Inc. on your radar as a leading force in the fight against cancer and infectious diseases.
Disclaimer
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.
AI
